Division of Allergy and Clinical Immunology, Department of Medicine, University of Colorado Denver, Aurora, CO 80045, USA.
J Immunol. 2010 Sep 1;185(5):3007-18. doi: 10.4049/jimmunol.1000156. Epub 2010 Jul 23.
Elevated expression of inhibitory receptors on virus-specific T cells has been implicated as a mechanism by which viruses evade host immune surveillance. Blockade of these pathways during chronic infection leads to increased T cell function and improved immune control of viral replication. To explore the association between costimulatory receptors and HIV replication, we examined the expression of programmed death 1 (PD-1), CTLA-4, T cell Ig domain and mucin domain 3 (TIM-3), and CD28 on HIV-specific CD4(+) T cells from HIV-infected subjects. Greater than 30% of HIV-specific CD4(+) T cells from untreated subjects coexpressed PD-1, CTLA-4, and TIM-3, whereas <2% of CMV- or varicella-zoster virus-specific CD4(+) T cells expressed all three receptors. Coexpression of all three inhibitory receptors on HIV-specific CD4(+) T cells was more strongly correlated with viral load compared with the expression of each receptor individually. Suppression of HIV replication with antiretroviral therapy was associated with decreased expression of all three inhibitory receptors on HIV-specific CD4(+) T cells. Surprisingly, a high percentage of HIV-specific CD4(+) T cells that expressed inhibitory receptors also coexpressed CD28. In vitro blockade of PD-1 binding concurrent with stimulation through CD28 synergistically increased HIV-specific CD4(+) T cell proliferation to a greater extent than did either alone. These findings indicate that HIV-specific CD4(+) T cell responses during chronic infection are regulated by complex patterns of coexpressed inhibitory receptors and that the synergistic effect of inhibitory receptor blockade and stimulation of costimulatory receptors could be used for therapeutic augmentation of HIV-specific CD4(+) T cell function.
病毒特异性 T 细胞上抑制性受体的高表达已被认为是病毒逃避宿主免疫监视的一种机制。在慢性感染期间阻断这些途径会导致 T 细胞功能增强,并改善对病毒复制的免疫控制。为了探讨共刺激受体与 HIV 复制之间的关联,我们检测了未经治疗的 HIV 感染者中 HIV 特异性 CD4+T 细胞上程序性死亡受体 1(PD-1)、细胞毒性 T 淋巴细胞相关抗原 4(CTLA-4)、T 细胞免疫球蛋白和粘蛋白结构域 3(TIM-3)和 CD28 的表达。未经治疗的受试者中超过 30%的 HIV 特异性 CD4+T 细胞共表达 PD-1、CTLA-4 和 TIM-3,而<2%的 CMV 或水痘带状疱疹病毒特异性 CD4+T 细胞表达这三种受体。与每种受体的表达相比,HIV 特异性 CD4+T 细胞上共表达所有三种抑制性受体与病毒载量的相关性更强。抗逆转录病毒治疗抑制 HIV 复制与 HIV 特异性 CD4+T 细胞上所有三种抑制性受体表达的降低相关。令人惊讶的是,表达抑制性受体的 HIV 特异性 CD4+T 细胞中有很高的比例也共表达 CD28。体外阻断 PD-1 结合并与 CD28 刺激同时进行可协同增加 HIV 特异性 CD4+T 细胞增殖,其程度大于单独使用任何一种方法。这些发现表明,慢性感染期间 HIV 特异性 CD4+T 细胞反应受到共表达抑制性受体的复杂模式调节,并且抑制性受体阻断和共刺激受体刺激的协同作用可用于增强 HIV 特异性 CD4+T 细胞功能的治疗。